title: Efficacy and toxicity of paclitaxel (Taxol) for the treatment of canine malignant tumors.
abstract: Paclitaxel (Taxol) was administered to 25 dogs with histologically confirmed malignant tumors at a dosage of 165 mg/m2 i.v. over 3-6 hours every 3 weeks. Dogs received premedication with antihistimines and corticosteroids to reduce hypersensitivity reactions. However, 64% of the dogs still experienced allergic reactions. Six dogs (24%) had grade 3 or 4 neutropenia, 6 dogs (24%) required hospitalization and 3 dogs (12%) died of sepsis. Five dogs (20%) had a partial response (osteosarcoma [2 dogs] mammary carcinoma [2 dogs] and malignant histiocytosis [1 dog]) for a median duration of 53 days. The overall toxicity was unacceptable at the 165 mg/m2 dose. Therefore, subsequent evaluations of paclitaxel in tumor-bearing dogs should a starting dose of 132 mg/m2 i.v. every 3 weeks.
authors.affiliation: Department of Medical Sciences, School of Veterinary Medicine, University of Wisconsin-Madison, 2015 Linden Drive, Madison, WI 53706, USA.
authors.forename: V J
authors.initials: VJ
authors.lastname: Poirier
authors.forename: A E
authors.initials: AE
authors.lastname: Hershey
authors.forename: K E
authors.initials: KE
authors.lastname: Burgess
authors.forename: B
authors.initials: B
authors.lastname: Phillips
authors.forename: M M
authors.initials: MM
authors.lastname: Turek
authors.forename: L J
authors.initials: LJ
authors.lastname: Forrest
authors.forename: L
authors.initials: L
authors.lastname: Beaver
authors.forename: D M
authors.initials: DM
authors.lastname: Vail
mesh_terms: D000818:Animals; D000972:Antineoplastic Agents, Phytogenic / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D003967:Diarrhea / Q000662:veterinary; D004283:Dog Diseases / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D004285:Dogs; D004334:Drug Administration Schedule; D005260:Female; D015994:Incidence; D007262:Infusions, Intravenous / Q000662:veterinary; D008297:Male; D015674:Mammary Neoplasms, Animal / Q000188:drug therapy*; D009503:Neutropenia / Q000662:veterinary; D012516:Osteosarcoma / Q000188:drug therapy / Q000662:veterinary*; D017239:Paclitaxel / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D011996:Records / Q000662:veterinary; D012189:Retrospective Studies; D016019:Survival Analysis; D013921:Thrombocytopenia / Q000662:veterinary; D014839:Vomiting / Q000662:veterinary; D014922:Wisconsin / Q000453:epidemiology
chemical_list: D000972:Antineoplastic Agents, Phytogenic; D017239:Paclitaxel